Cardiol Therapeutics Inc.
CRDLHealthcare|Drug Manufacturers - Specialty & Generic|CA
$0.99
+0.07 (+7.39%)
DCF Value
$0.15
Tangible Book / Share
$0.21
Cash / Share
$0.23
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06708299 CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) | Recurrent Pericarditis | P3 | Recruiting | 110 | RCT, Double-blind | CardiolRx |
| NCT04615949 Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors | COVID-19, Cardiovascular Diseases | P2P3 | Terminated | 90 | RCT, Double-blind | Cannabidiol, pharmaceutically produced with < 5 ppm THC, Placebo |
| NCT05494788 Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot) | Recurrent Pericarditis | P2 | Completed | 27 | Open-label | CardiolRx |
| NCT05180240 Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis | Acute Myocarditis | P2 | Completed | 109 | RCT, Double-blind | CardiolRx |